HEK293-CTLA4

305423

GENERAL INFORMATION

Description

□□□□□□□□□□□□□□□□□□□□/□□□□□□□□□□□□□□□□□ 6,250 □□
□□□□□□□□□□□□□□□□□□□□□□□□
□□□□□
HEK293-CTLA4□□□□□□□□□□□□HEK293□□□□□□□□□□□□□□□□□□□□□□□CTLA4□□□□□□□□4,000□□□□□□□□□□□inscreenex□□□□□□□□
□□□□CTLA4□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ CTLA4□□□CD152□□□□□□□□□□□□□□□□□T□□□□□□□□□□□□□□□
CTLA4□□□□□□□□□CD28□□□□□□□□□□□□□□□B7□□□CD80□CD86□□□□□□□□□□□□□□□□□□□□□□□□□□□CTLA4□□□□□□□□□□□□
□□□□□□□□□□□□□□ipilimumab□□□□□□□□□□□□□□□□□□□□□□□□T□□□□□□□□□□□□
□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□CTLA4□□□□□□□□□□□□□□□□□□□□□□□□□□□□□

Tissue	□□□□
Disease	□□/□□□□□□□□□□HEK293□□□

Applications

□□□□□□□□□□□□CTLA-4□□□□□□□□□□□□□□□□□□□□□□□□□□□□T□□□□□□□□□□□□□□□□□□□□□□□□□□

CLASSIFICATION

Organism	Human
Sex	Female
Growth properties	Adherent
GMO status	GMO-S1

GMO status details

GMO-S1: This HEK293 variant contains a CTLA-4 expression construct for immune checkpoint research. This classification applies only within Germany and may differ elsewhere.

Biosafety level	1

CHARACTERISTICS

Morphology	□□□
Cell type	□□□□
Doubling time	□24-36□□

IDENTIFIERS

Citation

HEK293-CTLA4 □Cytion □□□ 305423□

NCBI TaxID	9606
Cellosaurus	CVCL_6G20

EXPRESSION AND SUSCEPTIBILITY

Receptors expressed

CTLA4 (CD152)

HANDLING AND CULTURE

Culture medium

RPMI 1640□w□2.0 mM □□□□□□□w□2.0 g/L NaHCO3□Cytion □□□□ 820700a□□

Incubation atmosphere	37°C, 5%CO2, □□□□□

Supplements

□□□□□□□ 10% FBS□1 mM □□□□□10 mM HEPES □ 1% NEAA□□□□□□□G418-□□□□□□□□□□□□□ 1 mg/mL□

Dissociation reagent	□□□□-EDTA

Subculturing

□□□□□□□□□□□□□□□□□□□□□□□□□ PBS □□□□□□□□□□□□□□□ PBS □□□□□□□□□□□□□□□□□□□/EDTA □□□□ T25 □□ 1 □□□T75 □□ 3 □□□□□□□□ 37°C □□□□□□□□□5-10 □□□□□□□□□□□□□□□□□□□□

DONOR

Donor age	□□

LEGAL AND SAFETY

Safety precautions

□□□